Company registration number 14350059 (England and Wales)
NEWSON HEALTH GROUP LIMITED
ANNUAL REPORT AND FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 DECEMBER 2024
NEWSON HEALTH GROUP LIMITED
COMPANY INFORMATION
Directors
Dr L R Anderson
Dr R J Lewis
(Appointed 17 June 2024)
Mr M H P Daly
(Appointed 17 June 2024)
Company number
14350059
Registered office
Winton House
Church Street
Stratford upon Avon
Warwickshire
CV38 6HB
Auditor
Ormerod Rutter Limited
The Oakley
Kidderminster Road
Droitwich Spa
Worcestershire
WR9 9AY
NEWSON HEALTH GROUP LIMITED
CONTENTS
Page
Strategic report
1
Directors' report
2 - 3
Independent auditor's report
4 - 6
Statement of comprehensive income
7
Balance sheet
8
Statement of changes in equity
9
Notes to the financial statements
10 - 16
NEWSON HEALTH GROUP LIMITED
STRATEGIC REPORT
FOR THE YEAR ENDED 30 DECEMBER 2024
- 1 -

The directors present the strategic report for the year ended 30 December 2024.

Review of the business

The company operates as the parent entity of a group.

 

The financial results of the company are detailed in the annexed financial statements.

Principal risks and uncertainties

The directors consider that the principal risks and uncertainties facing the company are those relating to the value of investments in subsidiary companies.

Key performance indicators

The directors do not consider there to be any specific key performance indicators as the company operates as a holding company only.

On behalf of the board

Dr L R Anderson
Director
23 September 2025
NEWSON HEALTH GROUP LIMITED
DIRECTORS' REPORT
FOR THE YEAR ENDED 30 DECEMBER 2024
- 2 -

The directors present their annual report and financial statements for the year ended 30 December 2024.

Principal activities

The principal activity of the company in the year under review was that of a holding company.

Results and dividends

The results for the year are set out on page 8.

Ordinary dividends were paid amounting to £18,750. The directors do not recommend payment of a further dividend.

Directors

The directors who held office during the year and up to the date of signature of the financial statements were as follows:

Dr L R Anderson
Dr R J Lewis
(Appointed 17 June 2024)
Mr M H P Daly
(Appointed 17 June 2024)
Financial risk management objectives and strategy
Liquidity risk

The company manages its cash and borrowing requirements in order to maximise interest income and minimise interest expense, whilst ensuring the company has sufficient liquid resources to meet the operating needs of the business.

Future developments

The company has continued to trade as a holding company into the next financial period.

Auditor

Ormerod Rutter Limited were appointed as auditor to the company and in accordance with section 485 of the Companies Act 2006, a resolution proposing that they be re-appointed will be put at a General Meeting.

Statement of directors' responsibilities

The directors are responsible for preparing the annual report and the financial statements in accordance with applicable law and regulations.

 

Company law requires the directors to prepare financial statements for each financial year. Under that law the directors have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the company and of the profit or loss of the company for that period. In preparing these financial statements, the directors are required to:

 

 

The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the company’s transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

NEWSON HEALTH GROUP LIMITED
DIRECTORS' REPORT (CONTINUED)
FOR THE YEAR ENDED 30 DECEMBER 2024
- 3 -
Statement of disclosure to auditor

So far as each person who was a director at the date of approving this report is aware, there is no relevant audit information of which the company’s auditor is unaware. Additionally, the directors individually have taken all the necessary steps that they ought to have taken as directors in order to make themselves aware of all relevant audit information and to establish that the company’s auditor is aware of that information.

On behalf of the board
Dr L R Anderson
Director
23 September 2025
NEWSON HEALTH GROUP LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NEWSON HEALTH GROUP LIMITED
- 4 -
Opinion

We have audited the financial statements of Newson Health Group Limited (the 'company') for the year ended 30 December 2024 which comprise the statement of comprehensive income, the balance sheet, the statement of changes in equity and notes to the financial statements, including significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC’s Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Conclusions relating to going concern

In auditing the financial statements, we have concluded that the directors' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

 

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

 

Our responsibilities and the responsibilities of the directors with respect to going concern are described in the relevant sections of this report.

Other information

The other information comprises the information included in the annual report other than the financial statements and our auditor's report thereon. The directors are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

 

We have nothing to report in this regard.

Opinions on other matters prescribed by the Companies Act 2006

In our opinion, based on the work undertaken in the course of our audit:

NEWSON HEALTH GROUP LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NEWSON HEALTH GROUP LIMITED (CONTINUED)
- 5 -
Matters on which we are required to report by exception

In the light of the knowledge and understanding of the company and its environment obtained in the course of the audit, we have not identified material misstatements in the strategic report or the directors' report.

 

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

Responsibilities of directors

As explained more fully in the directors' responsibilities statement, the directors are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the directors determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error. In preparing the financial statements, the directors are responsible for assessing the company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the directors either intend to liquidate the company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Our approach to identifying and assessing the risks of material misstatement in respect of irregularities, including fraud and non-compliance with laws and regulations, was as follows:

 

We assessed the susceptibility of the company's financial statements to material misstatement, including obtaining an understanding of how fraud might occur, by:

 

NEWSON HEALTH GROUP LIMITED
INDEPENDENT AUDITOR'S REPORT
TO THE MEMBERS OF NEWSON HEALTH GROUP LIMITED (CONTINUED)
- 6 -

To address the risk of fraud through management bias and override of controls, we:

 

In response to the risk of irregularities and non-compliance with laws and regulations, we designed procedures which included, but were not limited to:

 

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

 

A further description of our responsibilities is available on the Financial Reporting Council’s website at: https://www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Use of our report

This report is made solely to the company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the company and the company's members as a body, for our audit work, for this report, or for the opinions we have formed.

William Jonathan Roberts FCCA
Senior Statutory Auditor
For and on behalf of Ormerod Rutter Limited
30 September 2025
Chartered Accountants
Statutory Auditor
The Oakley
Kidderminster Road
Droitwich Spa
Worcestershire
WR9 9AY
NEWSON HEALTH GROUP LIMITED
STATEMENT OF COMPREHENSIVE INCOME
FOR THE YEAR ENDED 30 DECEMBER 2024
- 7 -
2024
2023
Notes
£
£
Turnover
-
-
Administrative expenses
(3,486)
(3,312)
Other operating income
4,000
-
0
Operating profit/(loss)
514
(3,312)
Interest receivable and similar income
4
18,750
510,000
Amounts written off investments
6
1,162
(505,337)
Profit before taxation
20,426
1,351
Tax on profit
7
-
0
-
0
Profit for the financial year
20,426
1,351

The profit and loss account has been prepared on the basis that all operations are continuing operations.

NEWSON HEALTH GROUP LIMITED
BALANCE SHEET
AS AT
30 DECEMBER 2024
30 December 2024
- 8 -
2024
2023
Notes
£
£
£
£
Fixed assets
Investments
9
1,263
101
Current assets
Debtors
10
5,226
4,590
Cash at bank and in hand
200
100
5,426
4,690
Creditors: amounts falling due within one year
11
(3,462)
(3,240)
Net current assets
1,964
1,450
Net assets
3,227
1,551
Capital and reserves
Called up share capital
12
200
200
Profit and loss reserves
13
3,027
1,351
Total equity
3,227
1,551

These financial statements have been prepared in accordance with the provisions relating to medium-sized companies.

The financial statements were approved by the board of directors and authorised for issue on 23 September 2025 and are signed on its behalf by:
Dr L R Anderson
Director
Company registration number 14350059 (England and Wales)
NEWSON HEALTH GROUP LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 30 DECEMBER 2024
- 9 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 31 December 2022
100
-
0
100
Period ended 30 December 2023:
Profit and total comprehensive income
-
1,351
1,351
Issue of share capital
12
100
-
100
Balance at 30 December 2023
200
1,351
1,551
Year ended 30 December 2024:
Profit and total comprehensive income
-
20,426
20,426
Dividends
-
(18,750)
(18,750)
Balance at 30 December 2024
200
3,027
3,227
NEWSON HEALTH GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 DECEMBER 2024
- 10 -
1
Accounting policies
Company information

Newson Health Group Limited is a private company limited by shares incorporated in England and Wales. The registered office is Winton House, Church Street, Stratford upon Avon, Warwickshire, United Kingdom, CV38 6HB.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

This company is a qualifying entity for the purposes of FRS 102, being a member of a group where the parent of that group prepares publicly available consolidated financial statements, including this company, which are intended to give a true and fair view of the assets, liabilities, financial position and profit or loss of the group. The company has therefore taken advantage of exemptions from the following disclosure requirements:

 

 

The financial statements of the company are consolidated in the financial statements of Lapa Holdings Limited. These consolidated financial statements are available from its registered office, Winton House, Church Street, Stratford upon Avon, Warwickshire, CV37 6HB and Companies House.

1.2
Going concern

These financial statements have been drawn up on the going concern basis. If the going concern basis were not appropriate, adjustments would have been made to reduce assets to recoverable amounts, to provide for any further liabilities that might arise, and to re-classify fixed assets as current assets and long term liabilities as current liabilities.true

1.3
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

NEWSON HEALTH GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 DECEMBER 2024
1
Accounting policies
(Continued)
- 11 -

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.4
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.5
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Other financial assets

Other financial assets, including investments in equity instruments which are not subsidiaries, associates or joint ventures, are initially measured at fair value, which is normally the transaction price. Such assets are subsequently carried at fair value and the changes in fair value are recognised in profit or loss, except that investments in equity instruments that are not publicly traded and whose fair values cannot be measured reliably are measured at cost less impairment.

Impairment of financial assets

Financial assets, other than those held at fair value through profit and loss, are assessed for indicators of impairment at each reporting end date.

 

Financial assets are impaired where there is objective evidence that, as a result of one or more events that occurred after the initial recognition of the financial asset, the estimated future cash flows have been affected. If an asset is impaired, the impairment loss is the difference between the carrying amount and the present value of the estimated cash flows discounted at the asset’s original effective interest rate. The impairment loss is recognised in profit or loss.

 

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been, had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

NEWSON HEALTH GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 DECEMBER 2024
1
Accounting policies
(Continued)
- 12 -
Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.6
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.7
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

NEWSON HEALTH GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 DECEMBER 2024
- 13 -
2
Judgements and key sources of estimation uncertainty

In the application of the company’s accounting policies, the directors are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

 

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

3
Auditor's remuneration
2024
2023
Fees payable to the company's auditor and associates:
£
£
For audit services
Audit of the financial statements of the company
2,712
2,580
For other services
All other non-audit services
774
720
4
Interest receivable and similar income
2024
2023
£
£
Income from fixed asset investments
Income from shares in group undertakings
18,750
510,000
NEWSON HEALTH GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 DECEMBER 2024
- 14 -
5
Employees

There were no staff costs for the year ended 30 December 2024, nor for the period ended 30 December 2023. The company did not employ any members of staff in the current or prior year.

6
Amounts written off investments
2024
2023
£
£
Amounts written back to current loans
1,162
-
Impairment of fixed asset investments
-
(505,337)
1,162
(505,337)
Fixed asset investments have been impaired to their deemed value, following an assessment by the directors.
7
Taxation

The actual charge for the year can be reconciled to the expected charge for the year based on the profit or loss and the standard rate of tax as follows:

2024
2023
£
£
Profit before taxation
20,426
1,351
Expected tax charge based on the standard rate of corporation tax in the UK of 19.00% (2023: 19.00%)
3,881
257
Unutilised tax losses carried forward
(318)
(257)
Dividend income
(3,563)
-
0
Taxation charge for the year
-
-
8
Subsidiaries

Details of the company's subsidiaries at 30 December 2024 are as follows:

Name of undertaking
Registered office
Nature of business
Class of
% Held
shares held
Direct
Newson Health Limited
England and Wales
Health care
Ordinary
100.00
Balance App Limited
England and Wales
App development
Ordinary
100.00
NEWSON HEALTH GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 DECEMBER 2024
- 15 -
9
Fixed asset investments
2024
2023
Notes
£
£
Investments in subsidiaries
8
1,263
100
Investments in associates
-
0
1
1,263
101
Movements in fixed asset investments
Shares in subsidiaries and associates
£
Cost or valuation
At 31 December 2023
101
Additions
1,162
At 30 December 2024
1,263
Carrying amount
At 30 December 2024
1,263
At 30 December 2023
101
10
Debtors
2024
2023
Amounts falling due within one year:
£
£
Amounts owed by group undertakings
5,226
4,590
11
Creditors: amounts falling due within one year
2024
2023
£
£
Accruals and deferred income
3,462
3,240
NEWSON HEALTH GROUP LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 30 DECEMBER 2024
- 16 -
12
Share capital
2024
2023
2024
2023
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
0
80
-
0
80
Ordinary A shares of £1 each
0
20
-
0
20
Ordinary B shares of £1 each
0
20
-
0
20
Ordinary C shares of £1 each
0
80
-
0
80
Ordinary shares of 0.001p each
16,000,000
0
160
-
0
Ordinary A shares of 0.001p each
2,000,077
-
20
-
Ordinary B shares of 0.001p each
2,000,077
-
20
-
Ordinary C shares of 0.001p each
616
-
-
-
20,000,770
200
200
200

During the year, the company underwent a share reorganisation.

 

The company passed a special resolution by reclassifying 80 Ordinary C £1 shares into 80 Ordinary £1 shares. The rights and privileges attached to these shares remain unaltered.

 

Subsequently, the company then passed an ordinary resolution by subdividing the following shares:

 

160 Ordinary £1 shares into 16,000,000 Ordinary £0.00001 shares

20 Ordinary A £1 shares into 2,000,000 Ordinary A £0.00001 shares

20 Ordinary B £1 shares into 2,000,000 Ordinary B £0.00001 shares

 

The company then issued a further 77 Ordinary A £0.00001 shares, 77 Ordinary B £0.00001 shares and 616 Ordinary C £0.00001 shares.

13
Profit and loss reserves

The profit and loss reserve represents cumulative profits and losses, net of distributions paid.

14
Related party transactions

The company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

15
Ultimate controlling party

Ultimate parent company

The ultimate parent company is Lapa Holdings Limited, a company registered in England and Wales.

Ultimate controlling party

The ultimate controlling party is Dr L R Anderson and Dr P C B Anderson by virtue of their controlling interest in the ultimate parent company.

2024-12-302023-12-31falsefalsefalseCCH SoftwareCCH Accounts Production 2025.200Dr L R AndersonDr R J LewisMr M H P Daly0143500592023-12-312024-12-3014350059bus:Director12023-12-312024-12-3014350059bus:Director22023-12-312024-12-3014350059bus:Director32023-12-312024-12-3014350059bus:RegisteredOffice2023-12-312024-12-30143500592024-12-30143500592022-12-312023-12-3014350059core:RetainedEarningsAccumulatedLosses2022-12-312023-12-3014350059core:RetainedEarningsAccumulatedLosses2023-12-312024-12-30143500592023-12-3014350059core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3014350059core:CurrentFinancialInstrumentscore:WithinOneYear2023-12-3014350059core:ShareCapital2024-12-3014350059core:ShareCapital2023-12-3014350059core:RetainedEarningsAccumulatedLosses2024-12-3014350059core:RetainedEarningsAccumulatedLosses2023-12-3014350059core:ShareCapital2022-12-3014350059core:RetainedEarningsAccumulatedLosses2022-12-3014350059core:ShareCapitalOrdinaryShareClass12024-12-3014350059core:ShareCapitalOrdinaryShareClass12023-12-3014350059core:ShareCapitalOrdinaryShareClass22024-12-3014350059core:ShareCapitalOrdinaryShareClass22023-12-3014350059core:ShareCapitalOrdinaryShareClass32024-12-3014350059core:ShareCapitalOrdinaryShareClass32023-12-3014350059core:ShareCapitalOrdinaryShareClass42024-12-3014350059core:ShareCapitalOrdinaryShareClass42023-12-3014350059core:ShareCapitalOrdinaryShareClass52024-12-3014350059core:ShareCapitalOrdinaryShareClass52023-12-3014350059core:ShareCapitalOrdinaryShares2024-12-3014350059core:ShareCapitalOrdinaryShares2023-12-3014350059core:ShareCapital2022-12-312023-12-3014350059core:UKTax2023-12-312024-12-3014350059core:UKTax2022-12-312023-12-3014350059core:Subsidiary12023-12-312024-12-3014350059core:Subsidiary22023-12-312024-12-3014350059core:Subsidiary112023-12-312024-12-3014350059core:Subsidiary222023-12-312024-12-3014350059core:Non-currentFinancialInstruments2024-12-3014350059core:Non-currentFinancialInstruments2023-12-3014350059core:CurrentFinancialInstruments2024-12-3014350059core:CurrentFinancialInstruments2023-12-3014350059bus:OrdinaryShareClass12023-12-312024-12-3014350059bus:OrdinaryShareClass22023-12-312024-12-3014350059bus:OrdinaryShareClass32023-12-312024-12-3014350059bus:OrdinaryShareClass42023-12-312024-12-3014350059bus:OrdinaryShareClass52023-12-312024-12-3014350059bus:OrdinaryShareClass12024-12-3014350059bus:OrdinaryShareClass12023-12-3014350059bus:OrdinaryShareClass22024-12-3014350059bus:OrdinaryShareClass22023-12-3014350059bus:OrdinaryShareClass32024-12-3014350059bus:OrdinaryShareClass32023-12-3014350059bus:OrdinaryShareClass42024-12-3014350059bus:OrdinaryShareClass42023-12-3014350059bus:OrdinaryShareClass52024-12-3014350059bus:OrdinaryShareClass52023-12-3014350059bus:AllOrdinaryShares2024-12-3014350059bus:AllOrdinaryShares2023-12-3014350059bus:PrivateLimitedCompanyLtd2023-12-312024-12-3014350059bus:FRS1022023-12-312024-12-3014350059bus:Audited2023-12-312024-12-3014350059bus:FullAccounts2023-12-312024-12-30xbrli:purexbrli:sharesiso4217:GBP